Checkpoint Inhibition Plus Oncolytic Virus-Mediated Macrophage Reprogramming: A Triple-Modality Approach

The O’Connell et al. (2024) paper highlights TAM reprogramming (via PI3K-γ inhibition) as a strategy to enhance checkpoint therapy in TNBC, while Zhang et al. (2021, Thoracic Cancer) shows oncolytic viruses can reverse checkpoint resistance in NSCLC. This idea proposes a three-pronged regimen: (1) checkpoint blockade, (2) oncolytic virus to lyse tumor cells and expose antigens, and (3) a macrophage reprogramming agent (like eganelisib) to shift TAMs from suppressive to activating phenotypes. The novelty is the simultaneous targeting of multiple immune suppressive barriers, which has not yet been clinically tested as a unified approach. This could be particularly effective in tumors with dense stroma and high myeloid infiltration, offering a blueprint for “layered” immunotherapy regimens.

References:

1. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. Brenda O'Connell, Charley Hubbard, Nora Zizlsperger, Donna Fitzgerald, J. L. Kutok, Judith A. Varner, Robert Ilaria, M. Cobleigh, D. Juric, Kate H R Tkaczuk, Anthony D Elias, Arielle Lee, S. Dakhil, E. Hamilton, H. Soliman, Stephane Peluso (2024). Journal for ImmunoTherapy of Cancer.
2. Recombinant human adenovirus type 5 (Oncorine) reverses resistance to immune checkpoint inhibitor in a patient with recurrent non‐small cell lung cancer: A case report. Qianning Zhang, Yan Li, Qi Zhao, Mi Tian, Lu-Lu Chen, L. Miao, Yu-jie Zhou (2021). Thoracic Cancer.